| P50 | author | Helena Faust | Q56849218 |
| | Bettina Huber | Q59679480 |
| | Richard B S Roden | Q87305927 |
| | Kihyuck Kwak | Q89793910 |
| P2093 | author name string | Joakim Dillner | |
| | Reinhard Kirnbauer | |
| | Saeed Shafti-Keramat | |
| | Christina Schellenbacher | |
| | Dieter Fink | |
| | Christoph Jindra | |
| P2860 | cites work | Development of AAVLP(HPV16/31L2) particles as broadly protective HPV vaccine candidate | Q24288709 |
| | Global cancer statistics, 2002 | Q27860562 |
| | Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines | Q28246307 |
| | Against which human papillomavirus types shall we vaccinate and screen? The international perspective | Q28267023 |
| | VLPs displaying a single L2 epitope induce broadly cross-neutralizing antibodies against human papillomavirus | Q28280059 |
| | Immunogenic display of diverse peptides, including a broadly cross-type neutralizing human papillomavirus L2 epitope, on virus-like particles of the RNA bacteriophage PP7 | Q33569555 |
| | Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas | Q33707499 |
| | Common neutralization epitope in minor capsid protein L2 of human papillomavirus types 16 and 6 | Q33816200 |
| | Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan | Q34004909 |
| | Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments | Q34021545 |
| | Papillomavirus infection requires gamma secretase | Q34178325 |
| | Propagation, infection, and neutralization of authentic HPV16 virus | Q34316617 |
| | Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2. | Q34417608 |
| | A murine genital-challenge model is a sensitive measure of protective antibodies against human papillomavirus infection | Q35599310 |
| | Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2. | Q36314993 |
| | A protective and broadly cross-neutralizing epitope of human papillomavirus L2. | Q36315086 |
| | Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2. | Q36545925 |
| | Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins | Q36639439 |
| | Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles | Q36654802 |
| | Expression of human papillomavirus type 11 L1 protein in insect cells: in vivo and in vitro assembly of viruslike particles | Q36685977 |
| | Papillomavirus-like particles are an effective platform for amyloid-beta immunization in rabbits and transgenic mice | Q37219748 |
| | Serological relationship between cutaneous human papillomavirus types 5, 8 and 92 | Q37226380 |
| | Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic | Q37353496 |
| | Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines | Q37356046 |
| | A papillomavirus-like particle (VLP) vaccine displaying HPV16 L2 epitopes induces cross-neutralizing antibodies to HPV11. | Q37604412 |
| | Human papillomavirus type 26 infection causing multiple invasive squamous cell carcinomas of the fingernails in an AIDS patient under highly active antiretroviral therapy | Q37604419 |
| | Differences in human papillomavirus type distribution in high-grade cervical intraepithelial neoplasia and invasive cervical cancer in Europe | Q38023288 |
| | Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice | Q39742082 |
| | Identification of B-cell epitopes on virus-like particles of cutaneous alpha-human papillomaviruses | Q39793237 |
| | Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes | Q39999319 |
| | Titration of HPV-11 Infectivity and Antibody Neutralization Can Be Measured In Vitro | Q41301563 |
| | Human papillomavirus infection and incidence of squamous cell and basal cell carcinomas of the skin | Q42492102 |
| | Vaccination of cattle with the N-terminus of L2 is necessary and sufficient for preventing infection by bovine papillomavirus-4. | Q42675643 |
| | Prevalence of benign cutaneous disease among Oxford renal transplant recipients | Q44018201 |
| | Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study | Q45206974 |
| | Neutralization of CRPV infectivity by monoclonal antibodies that identify conformational epitopes on intact virions | Q45217723 |
| | Clinical features and age distribution of patients with HPV 2/27/57-induced common warts | Q45239995 |
| | Warts in primary schoolchildren: prevalence and relation with environmental factors. | Q51830513 |
| | β-Papillomavirus Infection and Skin Cancer | Q56637516 |
| | Mucosally-derived HPV-40 can infect both human genital foreskin and cutaneous hand skin tissues grafted into athymic mice | Q73343383 |
| | Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes | Q73740013 |
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 2706-2713 | |
| P577 | publication date | 2013-05-10 | |
| P1433 | published in | Journal of Investigative Dermatology | Q3186921 |
| P1476 | title | Efficacy of RG1-VLP vaccination against infections with genital and cutaneous human papillomaviruses | |
| P478 | volume | 133 | |